Crysvita® (burosumab-twza) – New orphan drug approval
April 17, 2018 - The FDA announced the approval of Ultragenyx and Kyowa Kirin’s Crysvita (burosumab-twza), for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.
Download PDF
